Publications
131 results found
Coupland NJ, Bailey JE, Wilson SJ, et al., 1994, A pharmacodynamic study of the alpha 2-adrenergic receptor antagonist ethoxyidazoxan in healthy volunteers, Clin.Pharmacol.Ther., Vol: 56, Pages: 420-429
Ethoxyidazoxan, a potent and highly selective alpha 2-adrenergic receptor antagonist, was administered intravenously to six healthy male volunteers in a double-blind, placebo-controlled, dose-rising design. Doses of 6 micrograms/kg and 8 micrograms/kg infused intravenously over 30 minutes produced significant elevations of plasma norepinephrine and body temperature and inhibited norepinephrine-induced platelet aggregation. Central activity was shown by reversal of the slowing of saccadic eye movements and an increase in saccade peak velocity at the higher dose. Modest increases in blood pressure were produced without change in heart rate. Ethoxyidazoxan was well tolerated, with slight changes in subjective alertness and sedation
Lillywhite AR, Wilson SJ, Nutt DJ, 1994, Successful treatment of night terrors and somnambulism with paroxetine, Br.J.Psychiatry, Vol: 164, Pages: 551-554
A patient with a 30-year history of somnambulism and night terrors is described. The use of a home ambulatory sleep electroencephalogram (EEG) recording in clarifying the diagnosis and in monitoring the results of treatment is illustrated and successful treatment using a selective serotonin re-uptake inhibitor is reported
Wilson SJ, Glue P, Ball D, et al., 1993, Saccadic eye movement parameters in normal subjects, Electroencephalogr.Clin.Neurophysiol., Vol: 86, Pages: 69-74
The present study obtained saccadic eye movements from 122 normal subjects to establish normative values and test-retest reliability data, using a recently developed electrooculographic recording and analysis system. Factors that might affect saccade values, such as age, sex, and time of day when testing, were also assessed. Mean (+/- S.D.) peak velocity values over saccade angles of 15 degrees, 25 degrees and 35 degrees were in agreement with those previously reported. Repeat testing in 11 subjects on 4 separate occasions showed that saccade measurements were consistent across tests. Several saccade parameters were significantly negatively associated with age for 35 degrees saccades. The association between age and peak velocity was examined in greater detail over a range of saccade angles, and the greatest effect was observed for saccades of > or = to 35 degrees. Diurnal changes in performance were observed, with a tendency for slightly slower values in the early afternoon. There were no significant differences between males and females
Glue PG, Wilson SJ, Ball DM, et al., 1992, Benzodiazepine sensitivity in subjects with high and low trait neuroticism., Biological Psychiatry
Glue PG, Wilson SJ, Campling G, et al., 1992, Alpha-2-adrenoceptor control of cortisol and ACTH in normal volunteers: preliminary open trial of the effects of acute and chronic idazoxan., Psychoneuroendocrinology, Vol: 17,2/3, Pages: 261-266
GLUE P, BAILEY J, WILSON S, et al., 1992, THYROTROPIN-RELEASING-HORMONE SELECTIVELY REVERSES LORAZEPAM-INDUCED SEDATION BUT NOT SLOWING OF SACCADIC EYE-MOVEMENTS, LIFE SCIENCES, Vol: 50, Pages: PL25-PL30, ISSN: 0024-3205
- Author Web Link
- Cite
- Citations: 14
Wilson SJ, Glue PG, Nutt DJ, 1992, Flumazenil and saccadic eye movements in patients with panic disorder and normal controls., Human Psychopharmacology, Vol: 7, Pages: 45-50
Wilson SJ, Glue PG, Nutt DJ, 1991, The effects of the �2-adrenoceptor antagonist idazoxan on sleep in normal volunteers., J.Psychopharm., Vol: 5,2, Pages: 105-110
Glue PG, Wilson SJ, Lawson C, et al., 1991, Acute and chronic idazoxan in normal volunteers: biochemical, physiological and psychological effects., J.Psychopharm., Vol: 5,4, Pages: 396-403
Glue PG, White E, Wilson SJ, et al., 1991, The pharmacology of saccadic eye movements (2): effects of the �2-adrenoceptor ligands idazoxan and clonidine., Psychopharmacology, Vol: 105, Pages: 368-373
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.